https://www.medscape.com/viewarticle/do-industry-payments-influence-end-life-cancer-care-2026a10013yr
Patients treated by oncologists who receive personal payments from drug manufacturers are more likely to receive aggressive end-of-life care, a large Medicare study found.
The differences were modest: Patients whose oncologists received industry payments had an 8% higher relative likelihood of receiving any anticancer treatment in their final 30 days, along with slightly higher likelihoods of receiving little or no hospice care, visiting an emergency department, or being hospitalized.
No hay comentarios:
Publicar un comentario